As a trusted partner to manufacturers of plasma-derived therapeutics and biologic drugs, CG Pharma & Biotech serves as an extended workbench for major (bio)pharma companies, supporting the industry's growing trend towards outsourcing buffers, process solutions and critical raw materials.
In response to the rapid growth of the biopharma industry in Europe, we meet the increasing demand for high-quality components essential in producing advanced
biopharmaceuticals, including monoclonal antibodies (mAbs), recombinant proteins, enzymes and vaccines.
We supply high-quality, GMP-compliant raw materials and customised formulations specifically designed for plasma processing and the manufacture of biological drugs and active ingredients (large molecules) derived from bacteria or mammalian cells.
With our promise “Your Challenge – Our Solution”, we commit to delivering flexible, tailored solutions that address the unique challenges of our clients. With the background of a family-owned company (CG Group), the business unit CG Pharma & Biotech is driven by a dedication to long-term partnerships and investment in client success, prioritising shared goals over corporate directives.
Our collaboration with industry and regulatory bodies, strengthened by our active involvement with BPI, positions us as advocates for a sustainable and secure biopharma industry in Europe.
Our key competencies include:
- Custom manufacturing of sterile-filtered process solutions and excipients for upstream and downstream biopharmaceutical applications
- Ready-to-use sterile-filtered solutions in single-use bags, ideal for various pharmaceutical processes
- GMP cleaning solutions for critical CIP (cleaning in place) and SIP (sterilisation in place) applications
- Expertise in processing hazardous substances in cleanrooms, including corrosive and flammable materials
- In-house production of water for injection (WFI) and active pharmaceutical ingredients (APIs), ensuring complete control over quality and compliance
- Pharmacopoeia-compliant raw materials for further use in the production of DS and DP
- Our scalable production capacity enables us to meet your needs flexibly, delivering “Made in Germany” quality at every step
Our History and achievements
With over 60 years of family-led expertise in high-quality chemical distribution, CG Chemikalien expanded its capabilities through the founding of CG Pharma & Biotech, enabling vertical integration to meet the complex needs of the pharmaceutical and biopharmaceutical industries.
| 2012 | Decision to build a new facility with temperature-controlled storage and GMP-compliant cleanroom production (Liquida and Solida areas) |
| 2014-2017 | Planning, construction, qualification and authority approval of the new production site |
| 2017/2018 | Production and release of the first products and first customer audit |
| 2022 | Foundation and renaming of business unit CG Pharma & Biotech |
| 2023 | Launch of PharmProve® brand (raw materials for bioprocessing) |
| 2025 | Liquid handling capability extension for concentrated corrosive chemicals under protected environment |
| 2025 | Project SolidPro, start of planning for and construction of a new GMP solid manufacturing plant |
| 2025 | Implementation of IPEC-GMP quality standard via EXCiPACT certification |
The Heart of CG Pharma & Biotech
At CG Pharma & Biotech, our dedicated team is the key to our success. With expertise in chemistry, biology, logistics and compliance, our professionals ensure the highest standards in every process and product. Their commitment to quality, flexibility and continuous development drives innovation and supports the creation of life-saving medicines.
Our Quality Commitment
Our operations adhere strictly to EU GMP guidelines (Parts 1 and 2) and align with ISO 9001:2015 requirements, underlined by a strict quality management system. Our facility is fully GMP-qualified, with validated processes and comprehensive cleanroom monitoring supported by a clean corridor concept.
We operate under a German manufacturing licence granted in accordance with Section 13 of the German Medicinal Products Act (AMG), meeting all obligations under the German regulatory framework for pharmaceutical production. Every batch undergoes a rigorous batch record review, with final release by authorised personnel to meet all regulatory requirements.
We are problem solvers for our customers. We find the right solutions for your requirements, challenges, quantities and constraints. With six locations, we offer a strong infrastructure across Germany and, thanks to our partner network, internationally as well. Our own logistics, warehouse management and a wide range of technical equipment make us autonomous, ensuring independent and reliable delivery at all times.
